UT Southwestern Study Finds Brain Cells Crucial to Endurance Performance
UT Southwestern Medical Center announced that new research identifies distinct brain cells that regulate endurance, showing stamina is not solely muscle‑based. The finding could pave the way for therapies that mimic exercise benefits for people unable to work out.
Ketone Ester Cut Alcohol Cravings in Small Study, Offering New Biohack
Researchers led by Xinyi Li reported that a single 395 mg/kg dose of a ketone ester supplement sharply reduced alcohol cravings in participants with alcohol use disorder and redirected brain metabolism from glucose to ketones. The pilot study, published in Psychiatry...
J&J Lifts 2026 Sales Outlook to $100 B, Defying Pricing Headwinds
Johnson & Johnson announced a 2026 sales guidance of $99.5‑$100.5 billion, topping the Street’s $98.9 billion consensus. The raise comes after a $3.05 billion acquisition and a pricing‑cost deal, underscoring strong oncology momentum and operational resilience.
FDA Issues Draft Guidance to Standardize Safety Assessment of Genome‑Editing Gene Therapies
The U.S. Food and Drug Administration today released a draft guidance titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next‑Generation Sequencing.” The document sets uniform pre‑clinical and IND requirements for ex vivo and in vivo CRISPR‑based...
Mabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)
Chinese biopharma Mabwell announced that the National Medical Products Administration has accepted a supplemental biologics license application for MAIWEIJIAN, its denosumab biosimilar. The 120 mg injection, already approved in China for giant cell tumor of bone and in Pakistan, is now...
Axtria Acquires Conexus Solutions to Fuse AI and CRM in Life Sciences
Axtria announced the acquisition of Conexus Solutions, a leading CRM transformation partner, to combine its agentic AI platform with Conexus' Veeva and Salesforce capabilities. The deal, disclosed on April 15, 2026, positions Axtria to deliver an integrated intelligence layer for...
Travere's FILSPARI Gains Full FDA Approval as First FSGS Therapy
Travere Therapeutics announced that the FDA has granted full approval to FILSPARI® (sparsentan) for adult and pediatric patients with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The decision makes FILSPARI the first and only FDA‑approved therapy for this rare kidney...
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
A new Cochrane Review of 17 clinical trials involving more than 20,000 participants found that anti‑amyloid drugs—including lecanemab and donanemab—produce only trivial cognitive benefits and modest functional gains over 18 months. The analysis also highlighted a higher incidence of brain...
Synthetic Biology Localizes Drug Production, Ending Fragile Supply Chains
Most pharmaceutical APIs still travel thousands of miles through fragile global supply chains before they reach a patient. COVID and the Russia-Ukraine war showed exactly what that fragility costs. Synthetic biology offers a different model: program cells to manufacture the molecules in...
Vaccines Vanishing Threatens Global Health Catastrophe
The Horrors That Could Lie Ahead if Vaccines Vanish — @propublica good article on the work of @NathanLo3579 @Stanford my former mentee and amazing colleague https://t.co/n9oUgkvOZ7
Spatial and Single-Cell Characterization of Human Glioblastoma Tumor Microenvironment Reveals Malignant Cellular Communities
The research combined spatial transcriptomics, single‑cell RNA sequencing, scATAC‑seq and Patch‑seq from 100 glioblastoma patients, covering 121 spatial profiles. It revealed four malignant cellular communities that consistently share cell‑type composition and gene‑expression patterns. Within these, two mesenchymal‑like tumor subpopulations were...
Glioblastoma's Immune Microenvironment Blocks Checkpoint Therapy
The glioblastoma tumor immune microenvironment (TIME) is an immunosuppressive barrier to therapy that encumbers glioblastoma responses to immune checkpoint inhibition (ICI). https://t.co/rgIKZ8N0Q4
Improving Immunotherapy in Solid Tumors Using FMT
Recent phase 2 trials demonstrate that fecal microbiota transplantation (FMT) significantly improves the efficacy of first‑line immune checkpoint inhibitors in renal cell carcinoma, cutaneous melanoma, and non‑small cell lung cancer. The benefit is linked to functional remodeling of the gut...
Enhancing Antitumour Nanovaccine Efficacy via Integrated Cholesterol Modulation in Situ
Researchers have created a nanovaccine, NPCM‑OT, that simultaneously delivers tumor antigens and depletes cholesterol from dendritic cell membranes. The cholesterol reduction reshapes lipid microdomains, enhancing immune‑synapse formation and CD8⁺ T‑cell activation. In multiple mouse tumor models, the vaccine showed both...
The Hallmarks of Cancer: 25 Years Guiding Discovery and Therapy
Twenty‑five years after the original six Hallmarks of Cancer were proposed, Douglas Hanahan updates the framework to incorporate new hallmarks such as deregulated metabolism, immune evasion, and the tumor microenvironment. Advances in genomics, single‑cell and spatial profiling have deepened insight...
Targeting Genomic Instability in Cancer
Genomic instability fuels cancer evolution and simultaneously creates therapeutic vulnerabilities. Decades of genotoxic chemotherapy and radiation have given way to precision approaches that exploit DNA‑damage response (DDR) defects, most notably PARP inhibitors for BRCA‑mutated tumors. The pipeline now includes dozens...
Quantum Computers Take on Health Care: Light-Sensitive Cancer Drugs Win US$2-Million Contest
A team comprising Algorithmiq, IBM, and the Cleveland Clinic secured the $2 million Quantum for Bio prize by demonstrating a hybrid quantum‑classical simulation of a light‑sensitive cancer drug. The approach models photon‑electron interactions on IBM’s Quantum System One, revealing how molecular...
The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework...
The FDA released two draft guidances in early 2026 that reshape gene‑therapy regulation. The Plausible Mechanism Framework (PMF) creates a formal pathway for individualized, ultra‑rare treatments, allowing single‑patient or tiny‑cohort data combined with mechanistic and natural‑history evidence to support marketing...
30 Top Media Leaders at SynBioBeta Can Make You Viral
📰 𝟯𝟬 𝗝𝗼𝘂𝗿𝗻𝗮𝗹𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗣𝗿𝗲𝘀𝘀 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗦𝘆𝗻𝗕𝗶𝗼𝗕𝗲𝘁𝗮 𝟮𝟬𝟮𝟲 𝘄𝗵𝗼 𝗰𝗼𝘂𝗹𝗱 𝗺𝗮𝗸𝗲 𝘆𝗼𝘂𝗿 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗴𝗼 𝘃𝗶𝗿𝗮𝗹 📰 With a combined reach of 500M+ monthly visitors, the journalists in the room at @SynBioBeta know how to get your work in front...
Singapore: AI Biochip Speeds Up Genetic Marker Detection to 20 Minutes
Scientists at Nanyang Technological University have unveiled an AI‑powered biochip that identifies disease‑linked microRNA markers in just 20 minutes using a single drop of blood. The nanophotonic chip amplifies fluorescent signals, while deep‑learning algorithms analyze thousands of nanocavities in real...
GLP-1s Don't Work for Everyone: Why, and What to Do?
GLP‑1 receptor agonists have become a cornerstone of modern weight‑loss therapy, yet roughly 20% of patients fail to achieve meaningful reductions. A recent review proposes pairing a GLP‑1 drug with the naltrexone‑bupropion combo (Contrave) to address this gap, leveraging complementary...
Single Blood Sample Could Soon Screen for Several Cancers, Study Suggests
UCLA researchers unveiled MethylScan, a low‑cost blood test that reads DNA methylation patterns in cell‑free DNA to flag multiple cancers and liver diseases from a single draw. By stripping out 80‑90% of background DNA, the assay slashes sequencing needs, driving...
Color Test 'Sniffs Out' Dangerous Staph Strains Fast
Researchers at RMIT University have created a rapid, low‑cost color‑changing test that distinguishes virulent and antibiotic‑resistant Staphylococcus aureus strains. The assay uses gold nanozyme particles and DNA aptamer binders to generate strain‑specific color fingerprints, functioning effectively in simulated wound fluid....
CUHK Trial Shows Flexible Fasting Plus Exercise Halves Fat Mass in Middle‑Aged Women
Researchers at the Chinese University of Hong Kong reported that a 12‑week program combining flexible time‑restricted eating with aerobic exercise more than doubled fat‑mass loss in overweight middle‑aged women, achieving a 10.2% reduction. The trial, involving 104 participants, also showed...
Elraglusib Doubles One‑Year Survival in Phase 2 Pancreatic Cancer Trial
Northwestern University’s experimental drug elraglusib, added to standard chemotherapy, cut the risk of death by 38% and doubled one‑year survival (44% vs. 22%) in a randomized Phase 2 trial of 233 patients with metastatic pancreatic cancer. Median overall survival rose to...
MASAI Trial Shows AI‑Augmented Mammography Beats Double Reading, Highlights FDA Gap
A Swedish randomized trial (MASAI) published in The Lancet shows that a radiologist paired with an AI algorithm detects breast cancer more accurately than two radiologists reading independently. The findings underscore a growing mismatch between clinical evidence and the FDA’s...
U.S. Health Officials Warn of Rising Extensively Drug‑Resistant Shigella Infections
U.S. health officials, including the CDC, warned that Shigella infections resistant to most antibiotics have risen sharply since 2011, with strains now classified as extensively drug‑resistant. The trend underscores a looming public‑health threat and a call for new antimicrobial and...
PrecisionLife and Ovation Target GLP-1 Response Variability with New Biomarker-Driven Collaboration
PrecisionLife and Ovation.io have teamed up to convert multi‑omic analyses of GLP‑1 receptor agonist use into predictive biomarker tools, including laboratory‑developed tests and a consumer DNA test. Early findings reveal separate biological drivers for glycemic control (HbA1c reduction) and weight...
Decoding the HRD Puzzle: Enhancing Precision Oncology Through Expanded Genomic Profiling-April 2, 2026
Labcorp announced an upgrade to its OmniSeq INSIGHT test, now incorporating an integrated homologous recombination deficiency (HRD) assessment powered by Illumina’s TSO500 workflow. The webinar detailed how genomic scar metrics—loss of heterozygosity, telomeric allelic imbalance, and large‑scale state transitions—correlate with response...
You're The Perfect Specimen
The blog post surveys a series of rapid‑changing trends, from GLP‑1 drugs turning into a massive, self‑directed health experiment to political leaders publicly disputing the Pope’s war doctrine. It highlights the cultural backlash against AI‑generated art, the surge of private‑equity...
IPSC Tissues Supply Causal Data to Power Simulations
A general-purpose biological simulator, one that can predict how the human body responds to any intervention, isn't blocked by compute. It's blocked by data. Not data in general. Causal, human-relevant data. The kind where molecular interactions actually produce functional outcomes you...
Bergamottin Reduces Cancer‑related Cachexia via Multiple Pathways
A Novel Role of Bergamottin in Attenuating Cancer Associated Cachexia by Diverse Molecular Mechanisms https://t.co/pr3d4kg0hB #mdpicancers
Spain Plants US$200m Flag in Boston with Debut US Biotech Fund
Spain has unveiled a $200 million venture‑capital fund based in Boston, anchored by $57 million of public seed capital. The fund will back Spanish life‑science startups seeking to scale within the U.S. ecosystem and co‑invest in select American biotech firms. A new...
Mutated TP53 Turns Tumor Suppressor Into Cancer Promoter
The TP53 gene makes the p53 protein, which normally helps prevent cancer by controlling cell growth and triggering damaged cells to die, but when it’s mutated it not only loses this protective role but can also help tumors grow. https://t.co/wPedodwV2U
Early GLP‑1 Rodent Studies Showed Weight Loss Before Diabetes Focus
I don't think this is correct from @nytimes op-ed on GLP-1s - wt loss known from early rodent studies involving injection into CSF as I recall. DM2 more tractable as initial pharma indication, esp at that time - many still...
Fujifilm Biotechnologies Opens New QC Lab in Denmark
Fujifilm Biotechnologies has opened a 2,000‑square‑meter GMP‑approved quality control laboratory at its Hillerød, Denmark site. The facility, designed for bioassay and virology work, will accommodate roughly 100 quality‑team members and features robotics, airlocks and a new LIMS for digital data...
New NEJM Review Links Hormone Therapy to Cardiovascular Risk
Sex hormones, clotting disorders, and cardiovascular risk An important new @NEJM review for MHT and testosterone latest data https://t.co/UNqXAwjsKM https://t.co/4ckJsc4YyE
FDA Reverses Ban on 12 Peptides for Review
So... @SecKennedy just announced that 12 peptides the Biden FDA shoved into "Category 2" — effectively banning them from regulated compounding pharmacies and driving people to the black market - are being pulled back for legitimate scientific review. Here's what each one...
Real-World Evoque Data Reassure, but It’s Still Early Days With TTVR
Early US real‑world data from the TVT Registry show that transcatheter tricuspid valve replacement (TTVR) with Edwards' Evoque device matches or modestly exceeds outcomes from the pivotal TRISCEND II trial. In 1,034 patients (average age 77, 69% female) 30‑day mortality was...
Retatrutide Poised to Become History’s Biggest Drug
Not s hot take, but I think retatrutide could be the largest drug in history @TravisHoium makes a great case on why the best way to play the emerging peptide market is $HIMS
Engineered Brain Cells Erase Alzheimer’s Proteins in Mice
Enhanced brain cells clear away dementia-related proteins New cellular immunotherapy approach for Alzheimer’s disease shows promise in mice https://t.co/YBoqUZLvJo https://t.co/FjG699Etga
New Drug Protects Against Life-Threatening Pancreatitis
A new RNA‑based drug, plozasiran, received its first clinical validation for a rare inherited disorder that causes extreme blood‑fat accumulation and recurrent acute pancreatitis. In the PALISADE trial, a single injection every three months lowered the risk of pancreatitis by...
Discover Cutting‑Edge Stem Cell Advances at BEYOND 2026
The best place to learn about the latest stem cell research is at BEYOND, Austin, TX, May 27-29, 2026. Learn all the new ways stem cell research is growing and becoming more available from @stemcellchristian at the BEYOND Biohacking Conference. https://t.co/e04Xnfyjwa
AI-Driven Precision Oncology Breakthrough From Korean Researchers
One unexpected but very insightful paper in Nature BJC from a leading institution in Korea on precision oncology and AI-driven drug discovery. I read it with great pleasure and you should read it too. https://t.co/vpxofjt9Mn https://t.co/SXs4n72CcY
CRISPR Variant Selectively Targets Tumor DNA
Researchers at Van Andel Institute and Wageningen University have engineered a CRISPR variant, ThermoCas9, that reads DNA methylation patterns to differentiate tumor DNA from healthy DNA. The enzyme selectively cuts methylated cancer sequences while sparing unmethylated normal genes, a finding published...
Elon Bets, GLP‑1 Relevance, and Consumer Sentiment Slump
🆓 Wednesday links: betting on Elon, why GLP-1 pills matter, and what's driving poor consumer sentiment. https://t.co/wCKQe3osVm image: https://t.co/QkWrhkJpqj https://t.co/aCwEbtyhzI
Practitioner Input Needed: AI Can't Perfect Cloning Tools
Cloning tools suck so much I decided to make my own, lol. Low hanging fruit yes, but without input from people who actually regularly do molecular cloning its the same like any other tool not made by practitioners of said...
Rapid Melatonin Test Can Help Astronauts and Others Easily Monitor Their Biological Rhythm
Washington State University researchers have created a 15‑minute melatonin test that combines a paper‑strip assay with a 3D‑printed smartphone fluorescence reader. The lateral‑flow immunoassay uses europium nanoparticles to achieve laboratory‑grade sensitivity of 10 picograms per milliliter, pinpointing the onset of an...
FDA Links Weight Loss Pill to ‘Unexpected’ Cardiovascular Risks
Eli Lilly’s oral GLP‑1 weight‑loss pill Foundayo (orforglipron) received FDA approval in early April, becoming the second oral GLP‑1 on the market after Novo Nordisk’s semaglutide. The agency’s approval letter, however, highlighted an unexpected serious risk of major adverse cardiovascular events, along...
InSPECt™ MS – Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis
The inSPECt™ MS platform combines native digestion with high‑resolution LC‑MS to quantify host‑cell proteins (HCPs) relative to spiked‑in protein standards. Calibration using the Cygnus Protein Standard demonstrated a linear response from 10 to 500 ppm with coefficients of variation under 18 %...